New strategies for enzyme replacement therapy for lysosomal storage diseases - Wikidata - awgldk - TriplyDB

New strategies for enzyme replacement therapy for lysosomal storage diseases

New strategies for enzyme replacement therapy for lysosomal storage diseases

http://www.wikidata.org/entity/Q34157148

about

Therapeutic efficacy of nanomedicines for prostate cancer: An update Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery Organelle targeting: third level of drug targeting Newborn screening and diagnosis of mucopolysaccharidoses Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.The final frontier -- crossing the blood-brain barrier.Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment.Blood-brain barrier structure and function and the challenges for CNS drug delivery.Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases.Mannose-6-phosphate receptor: a target for theranostics of prostate cancer.HIV Tat Domain Improves Cross-correction of Human Galactocerebrosidase in a Gene- and Flanking Sequence-dependent Manner.Bidirectional apical-basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells.Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.Delivery of Cargo to Lysosomes Using GNeosomes.Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1.

P2860

Q26766305-626B5BF1-84EE-41CA-BC4C-248124D0C069 Q26786070-AF91EFD7-43DD-435C-AFB5-860A04D0EA5E Q27014902-993CE413-5C3C-4660-87CC-80C1FEB2F450 Q27025080-BB166ABF-36F5-4A6C-A033-66366A73363D Q34679086-28A9F950-85BD-40B8-9E30-D03C2A61975B Q35690999-E0C709F6-6C3B-4A92-9B2D-AA7412E0AA9B Q36240723-C69B40EE-C0B3-4CFE-8E7C-08F95EC341B5 Q36482927-9AC9E3F3-A5C0-4DAA-AF68-9258B697258C Q36870076-F4C567AC-B30E-491B-B4E4-BBB2E734BB19 Q37714337-44E7F155-06E6-4931-99ED-DD3A78DBE085 Q37738056-3C2BE4A0-4DD4-4135-A969-DB69D5464B29 Q38100970-1A9C049F-5882-40DB-978A-B5726C6C322E Q38780921-62C54662-532E-4741-89E6-5F98C1D9C386 Q38895926-5D0A89E6-AE06-4A30-A62A-614FCAD9F2C0 Q39776866-CFDEAE9C-5949-49DC-8E4E-352FC56DF38A Q42507589-FC706892-BFAC-4DA6-8594-44DE1CADB172 Q43900510-3F35A081-80D4-4E7A-9AAF-3B43D725C10B Q50255169-B8013C16-2BA3-46F4-BEE4-C0807E934175 Q51733299-2766FC0F-FFDD-4B51-A0AA-4AB2FFE0510C Q55269135-54FB146B-831B-48D2-A4FA-5B7781C3EBDC

P2860

New strategies for enzyme replacement therapy for lysosomal storage diseases

http://www.wikidata.org/entity/Q34157148

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

New strategies for enzyme replacement therapy for lysosomal storage diseases

@ast

New strategies for enzyme replacement therapy for lysosomal storage diseases

@en

New strategies for enzyme replacement therapy for lysosomal storage diseases

@nl

type

label

New strategies for enzyme replacement therapy for lysosomal storage diseases

@ast

New strategies for enzyme replacement therapy for lysosomal storage diseases

@en

New strategies for enzyme replacement therapy for lysosomal storage diseases

@nl

prefLabel

New strategies for enzyme replacement therapy for lysosomal storage diseases

@ast

New strategies for enzyme replacement therapy for lysosomal storage diseases

@en

New strategies for enzyme replacement therapy for lysosomal storage diseases

@nl

P1433

Q34157148-154F1B85-422E-442A-9B19-D27E43A439CC

P1476

Q34157148-5F09F8C7-21BA-4DFC-8D61-EA2045B5DDF4

P2093

Q34157148-00002FCB-49A9-4B29-8363-9D75260305A1

Q34157148-69661C8E-568B-46BD-B218-CDB95E02D827

Q34157148-C96CDB3E-BC23-4F88-8D7F-C8C936992D93

P2860

Q34157148-0455A596-514A-4B19-872B-24AEA99EF4B4

Q34157148-0EEDB19F-F483-44C8-BCE2-884522049579

Q34157148-1EDBAFE5-9FA2-4C73-BBC5-CE5E76258B3B

Q34157148-249F9A25-773F-451A-8A11-915A4AAE95C0

Q34157148-3924D3E0-4AE3-43C2-9725-10E6295B5A5B

Q34157148-4BEADE1C-C363-4ADA-B1C9-8598AACA300F

Q34157148-4D5ACA49-1F60-4278-B0FA-1D2A6B581324

Q34157148-667CDC5D-71A9-40B0-9EB7-724A2B7A1242

Q34157148-67C2AC4C-CCF0-46F1-A427-138CDB1DC3CE

Q34157148-6E6F7E06-CDF7-4112-A043-88AE8C779842

P304

Q34157148-625E634A-6A41-4740-B51A-A0BD4E5B7BD5

P31

Q34157148-E512A4DA-954F-4701-A239-A2A76D6B13CC

P356

Q34157148-E6E3A378-EB7E-4C58-B782-4CBE4C4A0BF8

P407

Q34157148-7BACF92F-F898-4EE5-B47E-275B02B1BB0D

P433

Q34157148-23E539C7-B92C-4118-BB5E-E4BAF842404B

P478

Q34157148-0908636B-6B50-4BE2-8881-0F74EFC04057

P577

Q34157148-E9FB736D-AA70-42BE-80FB-2C69C6AA31FF

P5875

Q34157148-91683591-F1E6-4BF3-8986-C7B9ED4DB5A0

P698

Q34157148-C1FEEF83-B3FC-44A5-AEE0-57CD531E35E9

P921

Q34157148-0B44580D-3AA5-46F7-8BE1-5C8B9FEA153D

P932

Q34157148-67D09C1A-548A-4F87-941F-18242FFB84B8

P356

P1433

Rejuvenation Research

P1476

New strategies for enzyme replacement therapy for lysosomal storage diseases

@en

P2093

Carole Vogler

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Grubb

http://www.w3.org/2001/XMLSchema#string

William S Sly

http://www.w3.org/2001/XMLSchema#string

P2860

Mannose receptor-mediated regulation of serum glycoprotein homeostasis

Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy

Enzyme replacement therapy in a mouse model of aspartylglycosaminuria

Medical bioremediation: Prospects for the application of microbial catabolic diversity to aging and several major age-related diseases

Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.

Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

Transfer of antibody via mother's milk.

Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.

Lysosomal disorders.

P304

229-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/REJ.2009.0920

http://www.w3.org/2001/XMLSchema#string

P407

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42608013

http://www.w3.org/2001/XMLSchema#string

P698

20345279

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

2946059

http://www.w3.org/2001/XMLSchema#string